Cognition Therapeutics presented data in support of a phase 2 trial planned for CT1812, its lead candidate, in geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).
Tell me about CT1812.
CT1812 is an experimental oral sigma-2 (σ-2) receptor modulator currently undergoing phase 2 clinical trials for Alzheimer’s disease and dementia with Lewy bodies.
Let’s talk about the trials.
Two Alzheimer’s disease trials identified GA and macular degeneration as being notably associated with proteomic changes taking place in patient biofluids that were CT1812- vs placebo-treated. Additional assessments on proteomes revealed key proteins and pathways impaired in dry AMD and GA that significantly affected by CT1812. (via)
Anything else?
Investigators also conducted in vitro studies using retinal pigment epithelium (RPEs) obtained from induced pluripotent stem cells—cells that can self-renew by multiplying into different cells throughout the body and tissue—that had exposure to oxidative stress and amyloid beta oligomers.
What do these findings mean?
Data from the Alzheimer’s disease trials are evidence that CT1812 could have therapeutic potential in treating dry AMD. Similarity, the in vitro studies support CT1812 administration in allowing RPEs to recycle photoreceptor outer segments, an essential process that’s damaged by stressors
What’s next?
Cognition Therapeutics is currently in talks with the FDA to launch a phase 2 trial of 200+ patients diagnosed with GA.